PTCT logo

PTCT PTC Therapeutics, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$56.42
-1.91 (-3.27%)

PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of development—from early research and preclinical studies to clinical t…

Market Cap: $4.71Bwww.ptcbio.com

Price

No data yet.

Social Signal Score

66
5d
—
30d
65
4 mentions
—
60d
65
4 mentions
—
90d
67
6 mentions
—
news: 4 · rss: 2

Analyst Ratings

26 analysts
Buyconsensus
Strong Buy 0Buy 18Hold 6Sell 2Strong Sell 0
Avg price target$102.89+82.4%
Low $75Median $104High $137
Current Consensus

Revenue

$357.81M+1320.38%
$25.19M$408.83M$792.46M$1.18B
Dec 2016Sep 2026

Analyst Estimates

FY2025
$9.50
$6.66–$10.77
5 analysts
FY2026
$0.53-94% YoY
$-0.39–$0.99
7 analysts
FY2027
$2.73+419% YoY
$1.49–$4.47
7 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Matthew Klein
Sector
Healthcare
Industry
Biotechnology
Employees
991
Beta
0.51
Country
US
Piotroski score
4 / 9 (Middling)
Altman Z-score
0.69
www.ptcbio.com